Jounce Therapeutics, Inc. (NASDAQ:JNCE) is reporting third quarter earnings results on Friday 6th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.47 per share from $ 2.97 million in revenue.
For the full year, analysts predict revenues of $ 27.92 million, while looking forward to loss of $ 2.14 per share.
Stock Performance
Shares of Jounce Therapeutics, Inc. traded up $ 0.51 or 7.12 percent on Thursday, reaching $ 7.67 with volume of 335.10 thousand shares. Jounce Therapeutics, Inc. has traded high as $ 7.83 and has cracked $ 7.02 on the downward trend
According to the previous trading day, closing price of $ 7.67, representing a 151.23 % increase from the 52 week low of $ 2.85 and a 38.91 % decrease over the 52 week high of $ 11.72.
The company has a market capital of $ 262.43 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Jounce Therapeutics, Inc. will be hosting a conference call at 8:00 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.jouncetx.com
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase.
